New Zealand Becomes Latest Government to Approve ‘Shrooms' for Medicinal Use
But not everyone agrees with that assessment: New Zealand on Wednesday became the latest country to approve the use of the substance for therapeutic purposes.
David Seymour, New Zealand's Associate Minister for Health, told reporters that the new policy, which allows a single approved psychiatrist to prescribe psilocybin to patients with treatment-resistant depression, represents a ' real breakthrough.'
Seymour said that the psychiatrist, identified as Cameron Lacey, a professor at the University of Otago, 'has previously prescribed psilocybin in clinical trials and will operate under strict reporting and record-keeping requirements.' Seymour added that he is hoping more psychiatrists will apply for clearance to prescribe the drug to patients, though he clarified that the drug remains 'unapproved medicine.'
At the same time as the psilocybin policy change was announced, New Zealand announced plans to loosen restrictions on melatonin, which is used to treat insomnia and is sold over the counter in many other places. As Seymour promised to expand access to treatments like melatonin and psilocybin, no specific date was set for when they will be available across the country.
Where is the use of psilocybin for medicinal purposes legal?
New Zealand is not alone in permitting the medicinal use of the drug.
Australia, in July 2023, authorized specific psychiatrists to prescribe it for the treatment of certain mental health conditions.
In Switzerland, using LSD, MDMA, and psilocybin in medicine has been legal since 2014, for both research and treatment of mental health conditions.
And while the substance is generally illegal in Canada, regulated medical use is allowed under strict conditions.
Even some states in the U.S. have allowed some degree of use.
Oregon became the first state to legalize psilocybin's therapeutic use in 2020, though some cities have banned the drug. Still, in the state, access to the drug remains restricted: it may only be administered in a licensed psilocybin service center, and an administration session can cost up to $2,000, according to the Associated Press.
Colorado also legalized the regulated use of psilocybin for medical use in a ballot measure in 2022, with the first licenses for dispensing it issued earlier this year. And in April, New Mexico legalized psilocybin's use in approved settings to treat certain medical conditions.
Laws on the regulated medical use of psilocybin are also making their way through state legislatures like Minnesota and Massachusetts.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
13 hours ago
- Politico
Psychedelic medicine CEO eyes chances under MAHA
THE NEXT CURES As CEO of the psychedelic medicine company Compass Pathways, Kabir Nath has had a front-row seat to a dramatic year in the field of psychedelics. Once an industry darling, Compass' competitor Lykos Therapeutics was brought to its knees last summer when the Food and Drug Administration turned down the drugmaker's application for the psychedelic drug MDMA combined with talk therapy as a treatment for post-traumatic stress disorder. Lykos quickly shed staff and top leadership following the decision, including board member Rick Doblin, who spent decades campaigning for FDA approval of the drug. The rejection also had a chilling effect on the industry at large. Compass delayed results from its late-stage psychedelics trials and laid off 30 percent of its staff. But the environment has started to thaw in recent months. President Donald Trump's appointees, including HHS Secretary Robert F. Kennedy Jr. and VA Secretary Doug Collins, have sparked excitement among psychedelics proponents by touting psychedelic therapy's promise as a treatment for veterans with mental illness. In June, Kennedy offered a progress update on psychedelic therapies. 'We are working very hard to make sure that that happens within 12 months,' he told members of Congress. In late June, Compass released topline results from its Phase III trial of a synthetic form of psilocybin, which is derived from psychedelic mushrooms, as a therapy for treatment-resistant depression. While full findings won't be released until later this year, preliminary results found that after six weeks, a single dose of synthetic psilocybin reduced participants' depression scores by 3.6 points compared with a placebo group in a randomized trial of 258 people. Erin caught up with Nath to learn more about what's next for Compass and how the company is positioning itself under the new administration. This conversation has been edited for length and clarity. How are you feeling about your chances of FDA approval since Trump took office? We plan to meet with the FDA to discuss that and to talk about any potential for accelerating the filing. Right now, our base case continues to be that we will need both of the Phase III studies. The second one reads out at the second half in 2026, so that continues to be our base case, because that's the existing alignment we have with the agency. We're encouraged by the fact that there are voices in the administration at different levels who seem to share our view of the potential for psychedelics and share an interest in trying to get them accelerated, subject to doing the right rigorous studies and getting the science right. Which voices in the administration are you thinking of? What's in the public domain is that both RFK Jr. and Secretary Collins have talked about trying to find a way to make psychedelics available within 12 months. That has to be defined. Does that mean a full approval? Does that mean some sort of framework of early access? What we're excited to do is to find opportunities to partner if we can, so that whether it's earlier access, or whether it's some sort of pilot program, we could participate in that. But crucially, we want to respect the integrity of the FDA approval process. That's fundamental to us, because that is the gold standard for assuring safety and effectiveness. FDA Commissioner Marty Makary has also spoken publicly about psychedelics. There are a number of people who are on record saying they see the potential. But to be clear, we're not asking for psychedelic exceptionalism. We're not asking for a different standard. We've done two very large studies in patients with treatment-resistant depression, and we are two for two in showing highly statistically significant positive results after a single dose. In this population of really hard-to-treat depression, we think that is probably a unique achievement, but we'll call it remarkable. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Researchers at the University of Basel have reconstructed the 1918 Spanish flu virus from a 107-year-old lung, New Atlas reports. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. TECH MAZE Bruce Siegel, the outgoing president and CEO of America's Essential Hospitals, which represents hospitals that serve low-income patients, is retiring at the end of the year — after leading the group for 15 years and spending a nearly four-decade career in health policy and hospital administration. In an extended conversation with POLITICO's Kelly Hooper, he spoke about the impact of the tax legislation recently signed into law — containing more than $1 trillion in health care cuts — including new limits on provider taxes, work requirements and provisions that target Medicaid-directed payments and a $50 billion rural hospital fund Republicans included in the law to mitigate the impact on safety-net hospitals. Siegel also addressed the impact of technology on the health care sector. What might the future look like as new technology is increasingly integrated into care? I don't know how [artificial intelligence] plays out going forward. There's huge opportunities with AI to improve care, to predict what will happen to patients, to better communicate with patients. That's great. I also think that there's dangers in AI. Will AI increase disparities for some populations? It could. Could AI be used to redline communities or redline groups of patients? 'Hey, they're too risky.' Yeah, it could. There could be negative uses, and we're going to have to have some guardrails and a serious conversation about that. I was asked recently at a conference how I felt about the use of large data systems and AI to understand and inform how we treat the individual patient based on their genetics. And my response to that was that it could be very exciting, that level of personalized care, but would it also mean that my health data is now being bought and sold out there? And that's really valuable data. It's incredibly valuable data for underwriters, insurers, developers, all kinds of people. So we need to have some pretty firm understanding and some pretty firm guardrails around whose data is this and how it gets used. Read Siegel's full interview with Kelly on POLITICO Pro.
Washington Post
18 hours ago
- Washington Post
Study says ChatGPT giving teens dangerous advice on drugs, alcohol and suicide
ChatGPT will tell 13-year-olds how to get drunk and high, instruct them on how to conceal eating disorders and even compose a heartbreaking suicide letter to their parents if asked, according to new research from a watchdog group. The Associated Press reviewed more than three hours of interactions between ChatGPT and researchers posing as vulnerable teens. The chatbot typically provided warnings against risky activity but went on to deliver startlingly detailed and personalized plans for drug use, calorie-restricted diets or self-injury.
Newsweek
2 days ago
- Newsweek
Florida Officials Sound Alarm on Raw Milk, Children Among 21 Sick
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Six children are among 21 people infected with E. coli or campylobacter after drinking raw milk from a Florida farm, state health officials said Monday. Seven people have been hospitalized, at least two with severe complications, though the Florida Department of Health did not say whether any of the infected children under 10 are among those receiving hospital care, or how many illnesses were caused by each type of bacteria. In a public advisory, officials described the farm's sanitation practices as "of particular concern" but did not name the operation, which is located in northeast and central Florida. A dairy cow is milked at a farm in Newcastle, Maine, Tuesday, March 31, 2015. A dairy cow is milked at a farm in Newcastle, Maine, Tuesday, March 31, 2015. Associated Press Despite longstanding federal warnings that raw milk is one of the "riskiest" foods people can consume, unpasteurized dairy appears to be gaining popularity. The FDA and CDC warn that raw milk is far more likely than pasteurized milk to cause illnesses and hospitalizations because it can contain harmful bacteria such as campylobacter, listeria, salmonella and E. coli. These infections can lead to gastrointestinal illness and, in severe cases, life-threatening complications such as kidney failure — with children, the elderly, immunocompromised people and pregnant women at the highest risk. "We invented pasteurization for a reason," said Keith Schneider, a food safety professor at the University of Florida. "It's maddening that this is happening." In Florida, selling raw milk for human consumption is illegal, but retailers skirt the ban by labeling it as pet or animal food. Schneider called the practice a "wink, wink, nudge, nudge" form of regulation, noting that "everybody knows" it is being consumed by people. He said illnesses from raw milk are "not a question of if, but when." This article includes reporting by the Associated Press. This is a breaking news story. Updates to follow.
